Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).
2021-2022 New FDA Drug Approvals and New Indications
Use this resource to keep track of your clinical trials and key information needed when communicating with patients about a drug study.
Outcomes, misdiagnosis, diagnosis, Diagnostic criteria and treatmenet options for AOSD
Handouts to Dr. Len Calabreses TNR Presentation